Daniel D. Kaplan

NGM Biopharmaceuticals (United States) — United States

Immunology and Microbiology · Life Sciences

13h-index1.5kcitations96works0.42yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neutrophil, Myeloperoxidase and Oxidative Mechanisms(36), Chronic Myeloid Leukemia Treatments(22), Macrophage Migration Inhibitory Factor(16), Immune Cell Function and Interaction(15), Cell Adhesion Molecules Research(12)

Publications96 total

The scavenger receptor MARCO is a ligand for the immune inhibitory receptor LAIR-1 and regulates its function in cis

Science Signaling·2025

Combination targeting of myeloid cell stromal checkpoints 4738

The Journal of Immunology·2025Open Access

Abstract LB230: Generation of a B7-H4-restricted LTBR agonist to induce tertiary lymphoid structure formation in solid tumors

Cancer Research·2025

Figure S2 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S4 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S5 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Figure S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Data from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Figure S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S2 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S4 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Figure S4 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Figure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Figure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Table S2 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

Data from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors

2024Open Access

page 1 of 5Next →

Frequent Co-authors

Julie M. Roda(31), Vicky Y. Lin(29), Suzanne Crawley(27), Betty Li(27), Lee B. Rivera(26), Hung-I Harry Chen(25), Alan K. Kutach(25), Carmence Ho(23), James Sissons(23), Bin Fan(22), Kikuye Koyano(22), Peirong Chen(22), Jiawei Huang(21), Amir M. Ashique(21), Kevin J. Paavola(18), Christina Song(18), Avantika Kekatpure(18), Geoffrey W. Stone(17), Kyle O'Hollaren(16), Shelley Starck(16)